

Research Assistant Professor
University of Florida
Colleges of Medicine and Public Health & Health Professions
Department of Biostatistics
Children's Oncology Group (COG) Statistics & Data Center
6011 NW 1st Place, Suite 10, Gainesville, FL 32607
Phone: 352.273.0577
E-mail: anaranjo@cog.ufl.edu

Arlene H. Naranjo

Education

2002 – 2007 **University of Florida (UF)** **Gainesville, FL**

Doctor of Philosophy, Statistics

Dissertation topic: "State-Space Models with Exogenous Variables and Missing Data." Longitudinal data analysis with missing values from a state-space perspective. Includes theoretical and applied sections, with simulation studies and analysis of auto-immune diseases patient data related to research assistantship position.

2000 – 2002 **Florida International University** **Miami, FL**

Master of Science, Statistics

Thesis title: "Inferences About the Scale Parameter of the Gamma Distribution Based on Grouped and Partially Censored Data"

1996 – 2000 **Florida International University** **Miami, FL**

Bachelor of Science, Mathematical Sciences

Relevant Experience

2008 – Present **UF Children's Oncology Group** **Gainesville, FL**

Research Assistant Professor

- Design pediatric oncology clinical trials in neuroblastoma and renal tumors
- Conduct Kaplan-Meier survival analysis and Cox proportional hazards modeling
- Prepare technical reports and write statistical methodology and results sections for scientific papers
- Graduate Faculty status, for the purpose of serving on graduate students' supervisory committees

2006 – 2007 **University of Florida** **Gainesville, FL**

Graduate Research Assistant

- Prepared data collected from a pediatrics and an education study for analysis
- Conducted t-test, Wilcoxon rank sum, ANOVA, Kruskal-Wallis, regression, cluster, hierarchical linear model (HLM), receiver operating characteristic (ROC) curve, and area under the ROC curve analyses in SAS
- Presented results and developed topics for publication at team meetings
- Wrote statistical methodology and results sections in papers submitted for publication

2003 – 2006 **University of Florida** **Gainesville, FL**

Graduate Research Assistant

- Prepared data collected from patients with auto-immune diseases for analysis
- Conducted correlation, weighted regression, repeated measures, longitudinal, receiver operating characteristic (ROC) curve, and area under the ROC curve analyses in SAS
- Worked in a team environment to develop topics for research and publication
- Wrote statistical methodology and results section in papers submitted for publication

2002 – 2003 **University of Florida** **Gainesville, FL**

Graduate Teaching Assistant

- Taught 4 weekly sessions to complement introductory statistics course lectures
- Graded lab assignments, held office hours, and conducted exam review sessions

Summer 2002 **Florida International University** **Miami, FL**

Adjunct Instructor

- Taught Introduction to Statistics course
- Wrote, conducted, and graded quizzes and exams

2000 – 2002 **Florida International University** **Miami, FL**

Graduate Teaching Assistant

- Taught Introduction to Statistics during Fall and Spring semesters
- Graded student homework for other professors in the Department of Statistics
- Held tutoring sessions for students in lower-level statistics courses

Summers, 2000 – 2002 **Assurant Group** **Miami, FL**

Actuarial Intern

- Prepared new insurance product packages for filing in each state
- Conducted research for the development of new insurance products

Professional Activities

- Member of the American Statistical Association
- Member of the Society for Clinical Trials
- Reviewer for *Pediatric Blood & Cancer*
- Reviewer for *Statistics in Medicine*

Awards

- University of Florida Faculty Enhancement Opportunity (FEO) award (Fall 2012), intended to advance the academic/professional/scholarly activities and contribute to the professional career goals of faculty members
- GlaxoSmithKline Scholar Award (2002-2003), given each year to the most promising first-year graduate student in the Department of Statistics at the University of Florida

Languages/Skills

- Fluent in Spanish
- SAS, R/S-Plus
- Microsoft Office package (Word, Excel, Access, PowerPoint)
- LaTeX

Research Interests

- Clinical Trials Design & Analysis
- Survival Analysis
- Longitudinal Data Analysis
- Hierarchical Linear Models

Publications

1. Kibria, B. and **Naranjo, A.** (2002). Testing the Mean of Skewed Distributions: Chen's t_2 Test Revisited, *Pakistan Journal of Statistics* **18(2)**: 213–224.
2. Mi, J. and **Naranjo, A.** (2003). Inferences About the Scale Parameter of the Gamma Distribution Based on Data Mixed from Censoring and Grouping, *Statistics & Probability Letters* **62**: 229–243.
3. Barnes, E., Narain, S., **Naranjo, A.**, Shuster, J., Segal, M., Sobel, E., Armstrong, A., Santiago, B., Reeves, W., and Richards, H. (2005). High Sensitivity C-Reactive Protein in Systemic Lupus Erythematosus: Relation to Disease Activity, Clinical Presentation and Implications for Cardiovascular Risk, *Lupus* **14(8)**: 576–582.
4. Vermeulen, J., De Preter, K., **Naranjo, A.**, Vercruyssen, L., Van Roy, N., Hellemans, J., Swerts, K., Bravo, S., Scaruffi, P., Tonini, G.P., Noguera, R., Piqueras, M., Janoueix-Lerosey, I., Delattre, O., Combaret, V., Fischer, M., Oberthuer, A., Ambros, P., Beiske, K., Bénard, J., Marques, B., Michon, J., Schleiermacher, G., De Bernardi, B.,

- Rubie, H., Cañete, A., Castel, V., Kohler, J., Pötschger, U., Ladenstein, R., Hogarty, M.D., McGrady, P., London, W.B., Laureys, G., Speleman, F., and Vandesompele, J. (2009). Improved Outcome Prediction of Children with Neuroblastoma using a Multigene Expression Signature, a SIOPEN Study, *The Lancet Oncology* **10(7)**: 663–671.
5. Okamatsu, C.^(*), London, W.B., **Naranjo, A.**, Hogarty, M.D., Gastier-Foster, J.M., Look, A.T., LaQuaglia, M., Maris, J.M., Cohn, S.L., Matthay, K.K., Seeger, R.C., Saji, T., and Shimada, H. (2009). Clinicopathological Characteristics of Ganglioneuroma and Ganglioneuroblastoma: A Report from the CCG and COG Studies, *Pediatric Blood & Cancer* **53(4)**: 563–569.
 6. **Naranjo, A.**, Parisi, M.T., Shulkin, B.L., London, W.B., Matthay, K.K., Kreissman, S.G., and Yanik, G.A. (2011). Comparison of ¹²³I-Metaiodobenzylguanidine (MIBG) and ¹³¹I-MIBG Semi-Quantitative Scores in Predicting Survival in Patients with Stage 4 Neuroblastoma: A Report From the Children’s Oncology Group, *Pediatric Blood & Cancer* **56(7)**: 1041–1045. DOI: 10.1002/pbc.22991.
 7. Liu, Z.^(*), **Naranjo, A.**, and Thiele, C.J. (2011). CASZ1b, the Short Isoform of CASZ1 Gene, Coexpresses with CASZ1a during Neurogenesis and Suppresses Neuroblastoma Cell Growth, *PLoS ONE* **6(4)**: e18557. DOI:10.1371/journal.pone.0018557.
 8. Park, J.R., Scott, J., Stewart, C.F., London, W.B., **Naranjo, A.**, Santana, V.M., Shaw, P.J., Cohn, S.L., and Matthay, K.K. (2011). A Pilot Induction Regimen Incorporating Pharmacokinetically Guided Topotecan for Treatment of Newly Diagnosed High Risk Neuroblastoma: A Children’s Oncology Group Study (ANBL02P1). *Journal of Clinical Oncology* **29(33)**: 4351–4357. DOI: 10.1200/JCO.2010.34.3293.
 9. Villablanca, J.G., London, W.B., **Naranjo, A.**, McGrady, P., Ames, M.M., Reid, J.M., McGovern, R.M., Buhrow, S.A., Jackson, H., Stranzinger, E., Kitchen, B.J., Sondel, P.M., Parisi, M.T., Shulkin, B., Yanik, G.A., Cohn, S.L., and Reynolds, C.P. (2011). Phase II Study of Oral Capsular 4-Hydroxyphenylretinamide (4-HPR/Fenretinide) in Pediatric Patients with Refractory or Recurrent Neuroblastoma: A Report from the Children’s Oncology Group. *Clinical Cancer Research* **17(21)**: 6858–6866. DOI: 10.1158/1078-0432.CCR-11-0995.
 10. De Preter, K., Mestdagh, P., Vermeulen, J., Zeka, F., **Naranjo, A.**, Bray, I., Castel, V., Chen, C., Drozynska, E., Eggert, A., Hogarty, M.D., Izycka-Swieszewska, E., London, W.B., Noguera, R., Piqueras, M., Bryan, K., Schowe, B., Van Sluis, P., Molenaar, J.J., Schramm, A., Schulte, J.H., Stallings, R.L., Versteeg, R., Laureys, G., Van Roy, N., Speleman, F., and Vandesompele, J. (2011). miRNA Expression Profiling Enables Risk Stratification in Archived and Fresh Neuroblastoma Tumor Samples. *Clinical Cancer Research* **17(24)**: 7684–7692. DOI: 10.1158/1078-0432.CCR-11-0610.
 11. Daunic, A.P., Smith, S.W., Garvan, C.W., Barber, B.R., Becker, M.K., Peters, C.D., Taylor, G.G., Van Loan, C.L., Li, W., and **Naranjo, A.H.** (2012). Reducing Developmental Risk for Emotional/Behavioral Problems: A Randomized Controlled Trial Examining the Tools for Getting Along Curriculum. *Journal of School Psychology* **50(2)**: 149-166. DOI:10.1016/j.jsp.2011.09.003.
 12. Turnbull, C., Perdeaux, E.R., Pernet, D., **Naranjo, A.**, Renwick, A., Seal, S., Munoz-Xicola, R.M., Hanks, S., Slade, I., Zachariou, A., Warren-Perry, M., Ruark, E., Gerrard, M., Hale, J., Hewitt, M., Kohler, J., Lane, S., Levitt, G., Madi, M., Morland, B., Neefjes, V., Nicholdson, J., Picton, S., Pizer, B., Ronghe, M., Stevens, M., Traunecker, H., Stiller, C.A., Pritchard-Jones, K., Dome, J., Grundy, P., and Rahman, N. (2012). A Genome-Wide Association Study Identifies Susceptibility Loci for Wilms Tumor. *Nature Genetics* **44(6)**: 681–684. DOI: 10.1038/ng.2251.
 13. Granger, M., Grupp, S.A., Kletzel, M., Kretschmar, C., **Naranjo, A.**, London, W.B., and Diller, L. (2012). Feasibility of a Tandem Autologous Peripheral Blood Stem Cell Transplant Regimen for High Risk Neuroblastoma in a Cooperative Group Setting: A Pediatric Oncology Group Study: A Report from the Children’s Oncology Group. *Pediatric Blood & Cancer* **59(5)**: 902–907. DOI: 10.1002/pbc.24207.
 14. Khanna, G., **Naranjo, A.**, Hoffer, F., Mullen, E., Geller, J., Gratiyas, E.J., Ehrlich, P.F., Perlman, E.J., Rosen, N., Grundy, P., and Dome, J.S. (2013). Detection of Preoperative Wilms Tumor Rupture with CT: A Report from the Children’s Oncology Group. *Radiology* **266(2)**: 610-7. DOI: 10.1148/radiol.12120670.
 15. Suganuma, R.^(*), Wang, L.L., Sano, H., **Naranjo, A.**, London, W.B., Seeger, R.C., Hogarty, M.D., Gastier-Foster, J.M., Look, A.T., Park, J.R., Maris, J.M., Cohn, S.L., Amann, G., Beiske, K., Cullinane, C.J., d’Amore, E.S.G., Gambini, C., Jarzembowski, J.A., Joshi, V.V., Navarro, S., Peuchmaur, M., and Shimada, H. (2013). Peripheral Neuroblastic Tumors with Genotype-Phenotype Discordance: A Report from the Children’s Oncology Group and the International Neuroblastoma Pathology Committee. *Pediatric Blood & Cancer* **60(3)**: 363-70. DOI: 10.1002/pbc.24238.

16. Ostler, K.R., Yang, Q., Looney, T.J., Zhang, L., Vasanthakumar, A., Tian, Y., Kocherginsky, M., Raimondi, S.L., DeMaio, J.G., Salwen, H.R., Gu, S., Chlenski, A., **Naranjo, A.**, Gill, A., Peddinti, R., Lahn, B.T., Cohn, S.L., and Godley, L.A. (2012). Truncated DNMT3B Isoform DNMT3B7 Suppresses Growth, Induces Differentiation and Alters DNA Methylation in Human Neuroblastoma. *Cancer Research* **72(18)**: 4714-4723. DOI: 10.1158/0008-5472.CAN-12-0886.
17. Nuchtern, J.G., London, W.B., Barnewolt, C.E., **Naranjo, A.**, McGrady, P.W., Geiger, J.D., Diller, L., Schmidt, M.L., Maris, J.M., Cohn, S.L., and Shamberger, R.C. (2012). A Prospective Study of Expectant Observation as Primary Therapy for Neuroblastoma in Young Infants, a Children's Oncology Group Study. *Annals of Surgery* **256(4)**: 573-580. DOI: 10.1097/SLA.0b013e31826cbbbd.
18. Gow, K.W., Barnhart, D.C., Hamilton, T.E., Kandel, J.J., Chen, M.K.S., Ferrer, F.A., Price, M.R., Mullen, E.A., Geller, J.I., Gratias, E.J., Rosen, N., Khanna, G., **Naranjo, A.**, Ritchey, M.L., Grundy, P.E., Dome, J.S., and Ehrlich, P.F. (2013). Primary Nephrectomy and Intraoperative Tumor Spill: Report from the Children's Oncology Group (COG) Renal Tumors Committee. *Journal of Pediatric Surgery* **48(1)**: 34-8. DOI: 10.1016/j.jpedsurg.2012.10.015.
19. DuBois, S.G., Geier, E., Batra, V., Yee, S.W., Neuhaus, J., Segal, M., Martinez, D., Pawel, B., Yanik, G., **Naranjo, A.**, London, W.B., Kreisman, S., Baker, D., Attiyeh, E., Hogarty, M., Maris, J.M., Giacomini, K., and Matthay, K.K. (2012). Evaluation of Norepinephrine Transporter Expression and Avidity for Metaiodobenzylguanidine (MIBG) in Patients with Neuroblastoma: A Report from the Children's Oncology Group. *International Journal of Molecular Imaging*, 2012: 8 pages. DOI: 10.1155/2012/250834.
20. Yanik, G.A., Parisi, M.T., Shulkin, B.L., **Naranjo, A.**, Kreissman, S.G., London, W.B., Villablanca, J.G., Maris, J.M., Park, J.R., Cohn, S.L., McGrady, P., and Matthay, K.K. (2013). Semiquantitative MIBG Scoring as a Prognostic Indicator in Patients with Stage 4 Neuroblastoma. A Report from the Children's Oncology Group. *Journal of Nuclear Medicine* **54(4)**: 541-548. DOI: 10.2967/jnumed.112.112334.
21. **Naranjo, A.**, Trindade, A.A., and Casella, G. (2013). Extending the State-Space Model to Accommodate Missing Values in Responses and Covariates. *Journal of the American Statistical Association* **108(501)**: 202-216. DOI: 10.1080/01621459.2012.746066.
22. Dome, J.S., Fernandez, C.V., Mullen, E.A., Kalapurakal, J.A., Geller, J.I., Huff, V., Gratias, E.J., Dix, D.B., Ehrlich, P.F., Khanna, G., Malogolowkin, M.H., Anderson, J.R., **Naranjo, A.**, and Perlman, E.J., on behalf of the COG Renal Tumors Committee (2013). Children's Oncology Group's 2013 Blueprint for Research: Renal Tumors. *Pediatric Blood & Cancer* **60(6)**: 994-1000. DOI: 10.1002/pbc.24419.
23. Seif, A.E., **Naranjo, A.**, Baker, D.L., Bunin, N.J., Kletzel, M., Kretschmar, C.S., London, W.B., Maris, J.M., Park, J.R., Diller, L.R., and Grupp, S.A. (2013). ANBL00P1, A Children's Oncology Group Pilot Study of Tandem High Dose Chemotherapy with Stem Cell Rescue as Consolidation for High Risk Neuroblastoma. *Bone Marrow Transplantation* **48(7)**: 947-952. DOI: 10.1038/bmt.2012.276.
24. Levy, A.S., Pyke-Grimm, K.A., Lee, D.A., Palla, S.L., **Naranjo, A.**, Sholler, G.S., Gratias, E., Maloney, K., Parshankar, F., Lee-Scott, M., Beierle, E.A., Gow, K., Kim, G.E., Hunger, S., Smith, F.O., and Horton, T. (2013). Mentoring in Pediatric Oncology: A Report from the Children's Oncology Group Young Investigator Committee. *Journal of Pediatric Hematology & Oncology* **35(6)**: 456-461. DOI: 10.1097/MPH.0b013e31829eec33.
25. Wang, L.L., Sukanunma, R., Ikegaki, N., Tang, X., **Naranjo, A.**, London, W.B., Hogarty, M.D., Gastier-Foster, J.M., Look, A.T., Park, J.R., Maris, J.M., Cohn, S.L., Seeger, R.C., and Shimada, H. (2013). Neuroblastoma - Undifferentiated Subtype, Prognostic Significance of Prominent Nucleolar Formation and MYC Gene (MYCN and MYC) Expression: A Report from the Children's Oncology Group. *Cancer* **119(20)**: 3718-26. DOI: 10.1002/cncr.28251.
26. Hamilton, T.E., Barnhart, D., Gow, K., Ferrer, F., Kandel, J., Glick, R., Dasgupta, R., **Naranjo, A.**, He, Y., Gratias, E., Geller, J., Mullen, E., and Ehrlich, P. (2014). Inter-rater Reliability of Surgical Reviews for AREN03B2: A COG Renal Tumor Committee Study. *Journal of Pediatric Surgery* **49(1)**: 154-158. DOI: 10.1016/j.jpedsurg.2013.09.047.
27. Karlsson, J., Mengelbier, L.H., Ciornei, C., **Naranjo, A.**, O'Sullivan, M.J., and Gisselsson, D. (2014). Clear Cell Sarcoma of the Kidney Demonstrates an Embryonic Signature Indicative of a Primitive Nephrogenic Origin. *Genes, Chromosomes & Cancer* **53(5)**: 381-91. DOI: 10.1002/gcc.22149.
28. Libes, J.M., Seeley, E.H., Li, M., Axt, J.R., Pierce, J., Correa, H., Newton, M., Hansen, E., N'Dungu, J., Oruko, O., Githanga, J., Abdullah, F., Musimbi, J., Njuguna, F., Patel, K., Ellsworth, G., Mwachiro, M., White, R., Judd, A., McDonald, H., Caprioli, R.M., **Naranjo, A.**, Huff, V., O'Neill, J.A., and Lovvorn, H.N. (2014). Race Disparities in

Peptide Profiles of North American and Kenyan Wilms Tumor Specimens. *Journal of the American College of Surgeons* **218(4)**: 707-20. DOI: 10.1016/j.jamcollsurg.2013.12.044.

29. Ferrer, F.A., Herbst, K.W., Fernandez, C.V., Khanna, G., Dome, J.S., **Naranjo, A.**, Mullen, E.A., Geller, J.I., Gratias, E., Shamberger, R., Ritchey, M., and Ehrlich, P.F. (2014). Feasibility of Using CT Volume as a Predictor of Specimen Weight in a Subgroup of Patients with Low Risk Wilms Tumors Registered on COG Study AREN03B2: Implications for Central Venous Catheter Placement. *Journal of Pediatric Urology*. DOI: 10.1016/j.jpuro.2014.02.006.
30. Servaes, S., Khanna, G., **Naranjo, A.**, Geller, J.I., Ehrlich, P., Gow, K., Perlman, E., Dome, J.S., and Mullen, E. (2014). Comparison of Diagnostic Performance of CT and MRI for Abdominal Staging of Pediatric Renal Tumors: A Report from the Children's Oncology Group. *Pediatric Radiology*. DOI: 10.1007/s00247-014-3138-2.
31. Teshiba, R., Kawano, S., Wang, L.L., He, L., **Naranjo, A.**, London, W.B., Seeger, R.C., Gastier-Foster, J.M., Look, A.T., Hogarty, M.D., Cohn, S.L., Maris, J.M., Park, J.R., and Shimada, H. (2014). Age-Dependent Prognostic Effect by Mitosis-Karyorrhexis Index (MKI) in Neuroblastoma: A Report from the Children's Oncology Group. *Pediatric and Developmental Pathology* **17**: 441-9. DOI: 10.2350/14-06-1505-OA.1.
32. Geller, J.I., Ehrlich, P.F., Cost, N.G., Khanna, G., Mullen, E.A., Gratias, E.J., **Naranjo, A.**, Dome, J.S., Perlman, E.J. (2015). Characterization of Adolescent and Pediatric Renal Cell Carcinoma, a Report from the Children's Oncology Group Study AREN03B2. *Cancer* **121(14)**: 2457-64. DOI: 10.1002/cncr.29368.
33. Wang, L.L., Teshiba, R., Ikegaki, N., Tang, X.X., **Naranjo, A.**, London, W.B., Hogarty, M.D., Gastier-Foster, J.M., Look, A.T., Park, J.R., Maris, J.M., Cohn, S.L., Seeger, R.C., Asgharzadeh, S., and Shimada, H. (2015). Highly Aggressive Neuroblastoma with Augmented Expression of MYCN or MYC Protein: A Children's Oncology Group Study. *British Journal of Cancer* **113(1)**: 57-63. DOI: 10.1038/bjc.2015.188.
34. Eleveld, T.F., Oldridge, D.A., Bernard, V., Koster, J., Daage, L.C., Diskin, S.J., Schild, L., Bentahar, N.B., Bellini, A., Chicard, M., Lapouble, E., Combaret, V., Legoix-Né, P., Michon, J., Pugh, T.J., Hart, L.S., Rader, J., Attiyeh, E.F., Wei, J.S., Zhang, S., **Naranjo, A.**, Gastier-Foster, J.M., Hogarty, M.D., Smith, M.A., Auvil, J.M.G., Watkins, T.B.K., Zwijnenburg, D.A., Ebus, M.E., van Sluis, P., Hakkert, A., van Wezel, E., van der Schoot, C.E., Westerhout, E.M., Schulte, J.H., Tytgat, G.A., Dolman, M.E.M., Janoueix-Lerosey, I., Gerhard, D.S., Caron, H.N., Delattre, O., Khan, J., Versteeg, R., Schleiermacher, G., Molenaar, J.J., and Maris, J.M. (2015). Relapsed Neuroblastomas Show Frequent RAS-MAPK Pathway Mutations. *Nature Genetics* **47(8)**: 864-71. DOI:10.1038/ng.3333.
35. Temple, W., Mendelsohn, L., Kim, G.E., Nekritz, E., Gustafson, W.C., Lin, L., Giacomini, K., **Naranjo, A.**, Van Ryn, C., Yanik, G.A., Kreissman, S.G., Hogarty, M., Matthay, K.K., and DuBois, S.G. (2016). Vesicular Monoamine Transporter Protein Expression Correlates with Clinical Features, Tumor Biology, and MIBG Avidity in Neuroblastoma: A Report from the Children's Oncology Group. *European Journal of Nuclear Medicine and Molecular Imaging* **43(3)**: 474-81. DOI:10.1007/s00259-015-3179-2.
36. Bagatell, R., McHugh, K., **Naranjo, A.**, Van Ryn, C., Kirby, C., Brock, P., Lyons, K.A., States, L.J., Rojas, Y., Miller, A., Volchenboum, S.L., Simon, T., Krug, B., Sarnacki, S., Valteau-Couanet, D., von Schweinitz, D., Kammer, B., Granata, C., Pio, L., Park, J.R., and Nuchtern, J. (2016). Assessment of Primary Site Response in Children with High-Risk Neuroblastoma: An International Multicenter Study. *Journal of Clinical Oncology* **34(7)**: 740-6. DOI: 10.1200/JCO.2015.63.2042.
37. Ehrlich, P.F., Hamilton, T.E., Gow, K., Barnhart, D., Ferrer, F., Kandel, J., Glick, R., Dasgupta, R., **Naranjo, A.**, He, Y., Perlman, E.J., Kalapurakal, J.A., Khanna, G., Dome, J.S., Geller, J., and Mullen, E. (2016). Surgical Protocol Violations in Children with Renal Tumors Provides an Opportunity to Improve Pediatric Cancer Care: A Report from the Children's Oncology Group. *Pediatric Blood & Cancer* **63(11)**: 1905-10. DOI: 10.1002/pbc.26083.
38. Galli, S., **Naranjo, A.**, Van Ryn, C., Tilan, J., Trinh, E., Yang, C., Tsuei, J., Hong, S., Wang, H., Izycka-Swieszewska, E., Rodriguez, O., Albanese, C., and Kitlinska, J. (2016). Neuropeptide Y as a Biomarker and Therapeutic Target for Neuroblastoma. *American Journal of Pathology* **186(11)**: 3040-53. DOI: 10.1016/j.ajpath.2016.07.019.
39. Mazul, A.L., Siega-Riz, A.M., Weinberg, C.R., Engel, S.M., Zou, F., Carrier, K.S., Basta, P.V., Maris, J.M., Diskin, S.J., Vaksman, Z., Maxen, C., **Naranjo, A.**, and Olshan, A.F. (2016). A Family-Based Study of Gene Variants and Maternal Folate and Choline in Neuroblastoma: A Report from the Children's Oncology Group. *Cancer Causes and Control* **27(10)**: 1209-18. DOI:10.1007/s10552-016-0799-1.
40. Applebaum, M.A., Vaksman, Z., Hungate, E.A., Henderson, T.O., London, W.B., Pinto, N., Volchenboum, S.L., Park, J.R., **Naranjo, A.**, Hero, B., Pearson, A.D., Cohn, S.L., and Diskin, S.J. (2017). Neuroblastoma Survivors are at

Increased Risk for Second Malignancies: A Report from the International Neuroblastoma Risk Group Project. *European Journal of Cancer* 72: 177–85. DOI: 10.1016/j.ejca.2016.11.022.

41. DuBois, S.G., Mody, R., **Naranjo, A.**, Van Ryn, C., Russ, D., Oldridge, D., Kreissman, S., Baker, D.L., Parisi, M., Shulkin, B., Bai, H., Diskin, S., Batra, V., Maris, J.M., Park, J.R., Matthay, K.K., and Yanik, G. (2017). MIBG Avidity Correlates with Clinical Features, Tumor Biology, and Outcomes in Neuroblastoma: A Report from the Children's Oncology Group. *Pediatric Blood & Cancer*. DOI: 10.1002/pbc.26545.
42. Mody, R., **Naranjo, A.**, Van Ryn, C., Yu, A.L., London, W.B., Shulkin, B.L., Parisi, M.T., Servaes, S., Diccianni, M.B., Reisfeld, R.A., Gillies, S.D., Sondel, P.M., Maris, J.M., Park, J.R., and Bagatell, R. (2017). Randomized Phase II Trial of Irinotecan/Temozolomide with Temsirolimus or Dinutuximab plus Granulocyte Colony Stimulating Factor in Children with Refractory or Relapsed Neuroblastoma: A Report from The Children's Oncology Group (COG). *Lancet Oncology*. DOI: 10.1016/S1470-2045(17)30355-8.
43. Erbe, A.K., Wang, W., Reville, P.K., Carmichael, L., Kim, K., Mendonca, E.A., Song, Y., Hank, J.A., London, W.B., **Naranjo, A.**, Hong, F., Hogarty, M.D., Maris, J.M., Park, J.R., Ozkaynak, M.F., Miller, J.S., Gilman, A.L., Kahl, B., Yu, A.L., and Sondel, P.M. (2017). HLA-Bw4 Isoforms Differentially Influence Clinical Outcome in Monoclonal Antibody-Based Cancer Immunotherapy. *Frontiers in Immunology*. DOI: 10.3389/fimmu.2017.00675.
44. Campbell, K., Gastier-Foster, J., **Naranjo, A.**, Van Ryn, C., Bagatell, R., Matthay, K.K., London, W.B., Hogarty, M., Park, J.R., and DuBois, S.G. (2017). Association of MYCN Copy Number with Clinical Features, Tumor Biology, and Outcomes in Neuroblastoma: A Report from the Children's Oncology Group. *Cancer*.

Submitted

1. London, W.B., Bagatell, R., Weigel, B.J., Fox, E., Guo, D., Van Ryn, C., **Naranjo, A.**, Krailo, M., and Park, J.R. (2017). Historical Standard for Time-to-Progression (TTP) and Progression-Free Survival (PFS) in Relapsed/Refractory Neuroblastoma Modern Era (2002-14) Patients from Children's Oncology Group (COG) Trials. *Cancer*.
2. Yanik, G.A., Parisi, M.T., **Naranjo, A.**, Nadel, H., Gelfand, M.J., Park, J.R., Ladenstein, R.L., Poetschger, U., Boubaker, A., Valteau-Couanet, D., Lambert, B., Castellani, M., Bar-Sever, Z., Oudoux, A., Kaminska, A., Kreissman, S.G., Shulkin, B.L., and Matthay, K.K. (2017). Validation of Post-Induction Curie Scores in High-Risk Neuroblastoma. A Children's Oncology Group (COG) and SIOPEN Group Report on SIOPEN/HR-NBL-1. *Journal of Nuclear Medicine*.
3. Ladenstein, R. and Lambert, B., Pötschger, U., Lewington, V., Castellani, M., Bar-Sever, Z., Oudoux, A., Kaminska, A., Taborska, K., Biassoni, L., Yanik, G.A., **Naranjo, A.**, Parisi, M.T., Shulkin, B.L., Nadel, H., Gelfand, M.J., Matthay, K.K., Park, J.R., Kreissman, S.G., Valteau-Couanet, D., and Boubaker, A. (2017). Validation of the mIBG Skeletal SIOPEN Scoring Method in Two Independent High Risk Neuroblastoma Populations: The COG-A3973 and SIOPEN/HR-NBL1 Trials. *Journal of Nuclear Medicine*.
4. Mazul, A.L., Weinberg, C.R., Engel, S.M., Siega-Riz, A.M., Zou, F., Carrier, K.S., Basta, P.V., Vaksman, Z., Maris, J.M., Diskin, S.J., Maxen, C., **Naranjo, A.**, and Olshan, A.F. Neuroblastoma in Relation to Joint Effects of Vitamin A and Maternal and Offspring Variants in Vitamin A-Related Genes: A Report of the Children's Oncology Group. *Paediatric and Perinatal Epidemiology*.
5. Erbe, A.K., Wang, W., Carmichael, L., Kim, K., Mendonça, E.A., Song, Y., Hess, D., Reville, P.K., London, W.B., **Naranjo, A.**, Hank, J.A., Diccianni, M.B., Reisfeld, R.A., Gillies, S.D., Matthay, K.K., Cohn, S.L., Hogarty, M.D., Maris, J.M., Park, J.R., Ozkaynak, M.F., Gilman, A.L., Yu, A.L., and Sondel, P.M. (2017). Neuroblastoma Patients' KIR and KIR-ligand Genotypes Influence Clinical Outcome for Dinutuximab-Based Immunotherapy. *Cancer Discovery*.

In Revision

1. De Alarcon, P.A., Matthay, K.K., London, W.B., **Naranjo, A.**, Tenney, S.C., Panzer, J.A., Hogarty, M.D., Park, J.R., Maris, J.M., and Cohn, S.L. A Randomized Trial of Intravenous Immunoglobulin (IVIG) with Prednisone and Risk-Adapted Chemotherapy for Children with Opsoclonus Myoclonus Ataxia Syndrome (OMA) Associated with Neuroblastoma: Children's Oncology Group Study ANBL00P3. *Lancet Oncology*.
2. **Naranjo, A.**, Irwin, M.S., Hogarty, M.D., Cohn, S.L., Park, J.R., and London, W.B. Statistical Framework for the Revised International Neuroblastoma Risk Group Staging System (INRGSS) Risk Classification System.

- Alexander, N., Marrano, P., Thorner, P., **Naranjo, A.**, Van Ryn, C., Martinez, D., Batra, V., Zhang, L., Irwin, M.S., Baruchel, S. Prevalence and Clinical Correlations of Somatostatin Receptor-2 (SSTR2) Expression in Neuroblastoma.
- Cho, H., Sonawane, P., **Naranjo, A.**, Van Ryn, C., Yang, S., Yu, A.L., Park, J.R., Kreisman, S., Villablanca, J.G., Reynolds, C.P., and Kang, M.H. Low Plasma Levels of 13-Cis-Retinoic Acid (Isotretinoin) and its Active Metabolite 4-Oxo-13-Cis-Retinoic Acid Are Associated with Lower Overall Survival of High-Risk Neuroblastoma Patients.
- Ozkaynak, M.F., Gilman, A.L., Yu, A.L., London, W.B., **Naranjo, A.**, Tenney, S., Diccianni, M.B., Smith, M., Messer, K.S., Seeger, R., Reynolds, C.P., Smith, L.M., Shulkin, B.L., Parisi, M., Maris, J.M., Park, J.R., and Sondel, P.M. A Comprehensive Safety Trial of Chimeric Antibody 14.18 with GM-CSF, IL-2 (ImmRx) and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: A Children's Oncology Group Study. *Clinical Cancer Research*.
- Teshiba, R., Matsuno, R., Wang, L.L., Ikegaki, N., Tang, X.X., **Naranjo, A.**, Van Ryn, C., London, W.B., Hogarty, M.D., Gastier-Foster, J.M., Look, A.T., Park, J.R., Maris, J.M., Cohn, S.L., Seeger, R.C., Asgharzadeh, S., and Shimada, H. MYC-Family Protein Overexpression and Prominent Nucleolar Formation Signify Adverse Prognostic Effects in High-MKI Neuroblastomas: A Report from the Children's Oncology Group. *Clinical Cancer Research*.
- Roberts, J.K., Wu, W., Wu, J., **Naranjo, A.**, Daryani, V.M., Gajjar, A.J., Park, J.R., and Stewart, C.F. Population Pharmacokinetics of Topotecan in a Pediatric High-Risk Neuroblastoma Clinical Trial Utilizing a Single Sample Approach.
- Daunic, A.P., **Naranjo, A.**, Garvan, C.W., and Smith, S.W. Use of Behavioral Assessments from Multiple Informants to Identify Children at Risk for Externalizing Behavior Problems. *School Psychology Review*.

Presentations

- Naranjo, A.** (2009, September 30; Oral). *The Youden Index*, Children's Oncology Group Fall 2009 Meeting, Dallas, TX.
- Naranjo, A.**, Parisi, M.T., Shulkin, B.L., London, W.B., Matthay, K.K., Kreissman, S.G., and Yanik, G.A. (2010, June 22; Poster). *Comparison of I-123 and I-131 mIBG Scans in Predicting Survival in Patients with Stage 4 Neuroblastoma*, Advances in Neuroblastoma Research conference, Stockholm, Sweden.
- Naranjo, A.**, Maldonado-Molina, M.M., Komro, K.A., Trindade, A.A., and Casella, G. (2010, August 5; Oral). *Estimation in State-Space Models with Exogenous Covariates and Missing Data*, Joint Statistical Meeting, Vancouver, British Columbia, Canada.
- Naranjo, A.**, Parisi, M.T., Shulkin, B.L., London, W.B., Matthay, K.K., Kreissman, S.G., and Yanik, G.A. (2010, September 23; Poster). *Comparison of I-123 and I-131 mIBG Semi-Quantitative Scores in Predicting Survival in Patients with Stage 4 Neuroblastoma: A Report from the Children's Oncology Group*, Children's Oncology Group Fall 2010 Meeting, Dallas, TX.
- Naranjo, A.** (2011, March 23; Oral). *Survival Tree Regression Analysis of A3961 and P9641 Patients*, as part of the Non High-Risk Task Force presentation by Meany, H., Children's Oncology Group Spring 2011 Meeting, Los Angeles, CA.

Contributed Presentations

- Daunic, A.P., Smith, S.W., Garvin, C., **Naranjo, A.**, Barber, B., Becker, M., Heidenescher, S., Peters, C., Taylor, G. (2007, July; Poster). *First Year Progress of a Universal Cognitive-Behavioral Intervention for Elementary Students to Reduce Disruptive/Aggressive Behavior*, U.S. Department of Education, Institute of Education Sciences 2007 Research Conference, Washington, DC.
- Daunic, A.P., Becker, M., Barber, B., Peters, C., Smith, S.W., **Naranjo, A.** (2007, October; Poster). *Assessing teacher behaviors that relate to socio-emotional learning: The Multi-Informant Teacher Assessment System*, 7th Biennial International Conference on Children and Youth with Behavioral Disorders, Dallas, TX.
- Daunic, A.P., Smith, S.W., **Naranjo, A.**, Garvan, C., Barber, B.R., Becker, M., Peters, C., Taylor, G., Van Loan, C. (2008, March; Poster). *Universal Cognitive-Behavioral Intervention to Reduce Aggression among 4th and 5th Grade Students: First Year Results*, Annual Meeting of the American Educational Research Association, New York, NY.

4. Smith, S.W., Daunic, A.P., **Naranjo, A.**, Garvan, C., Barber, B.R., Becker, M., Peters, C., Taylor, G., Van Loan, C. (2008, April; Poster). *Reducing Classroom Disruptive/ Aggressive Behavior: Year One Findings from a Universal/ Selective Intervention*, Council for Exceptional Children – 86th Annual Convention, Boston, MA.
5. Smith, S.W., Daunic, A.P., Garvan, C., **Naranjo, A.**, Barber, B., Becker, M., Peters, C., Taylor, G., Van Loan, C. (2008, July; Poster). *Universal cognitive-behavioral intervention to reduce disruptive/aggressive behavior: Findings from Year 1*, U.S. Department of Education, Institute of Education Sciences 2008 Research Conference, Washington, DC.
6. Vermeulen, J., De Preter, K., **Naranjo, A.**, Vercruyse, L., Van Roy, N., Hellemans, J., Swerts, K., Bravo, S., Scaruffi, P., Tonini, G.P., Noguera, R., Piqueras, M., Janoueix-Lerosey, I., Delattre, O., Fischer, M., Oberthuer, A., Combaret, V., Beiske, K., Bénard, J., Ambros, P., Marques, B., Michon, J., Schleiermacher, G., Di Bernardi, B., Rubie, H., Cañete, A., Pötschger, U., Ladenstein, R., Hogarty, M.D., McGrady, P., London, W.B., Laureys, G., Speleman, F., Vandesompele, J. (2009, February 13; Poster). *Improved Outcome Prediction of Children with Neuroblastoma using a Multigene Expression Signature, a SIOPEX Study*, 9th BeSHG meeting, Darwin's 200th Birthday, Brussels, Belgium.
7. Escoto, H., London, W.B., McGrady, P., **Naranjo, A.**, Li, L., Wooten-Blanks, L., Kravaka, J.M. (2009, March 11–14; Oral). *Association of High Ceramide Levels with Unfavorable Neuroblastoma Risk Factors: A Report from the Children's Oncology Group*, 5th International Charleston Ceramide Conference, Charleston, SC.
8. Vermeulen, J., De Preter, K., **Naranjo, A.**, Vercruyse, L., Van Roy, N., Hellemans, J., Swerts, K., Bravo, S., Scaruffi, P., Tonini, G.P., Noguera, R., Piqueras, M., Janoueix-Lerosey, I., Delattre, O., Fischer, M., Oberthuer, A., Combaret, V., Beiske, K., Bénard, J., Ambros, P., Marques, B., Michon, J., Schleiermacher, G., Di Bernardi, B., Rubie, H., Cañete, A., Pötschger, U., Ladenstein, R., Hogarty, M.D., McGrady, P., London, W.B., Laureys, G., Speleman, F., Vandesompele, J. (2009, November 13; Oral). *Prospective Evaluation of Molecular Signatures for Risk Stratification in Future SIOPEX Clinical Trials*, Translational Genomics in Neuroblastoma (TGiN)-3 Meeting, Bethesda, MD.
9. Parisi, M., Shulkin, B., **Naranjo, A.**, McGrady, P., London, W., Kreissman, S., Yanik, G. (2010, June; Oral). *Impact of MIBG Scores on Predicting Survival in High Risk Neuroblastoma Patients*, Society of Nuclear Medicine meeting, Salt Lake City, UT.
10. Parisi, M., Shulkin, B., **Naranjo, A.**, McGrady, P., London, W., Kreissman, S., Yanik, G. (2010, June; Oral). *MIBG Scores: A Means of Identifying an Ultra-High Risk Group of Patients*, Society of Nuclear Medicine meeting, Salt Lake City, UT.
11. Yanik, G.A., Parisi, M.T, **Naranjo, A.**, Matthay, K.K., London, W.B., McGrady, P.W., Kreissman, S.G., Shulkin, B.L. (2010, June 7; Oral). *MIBG Scoring as a Prognostic Indicator in Patients with Stage IV Neuroblastoma: A COG Study*, American Society of Clinical Oncology meeting, Chicago, IL.
12. Irwin, M.S., **Naranjo, A.**, Attiyeh, E.F., Seeger, R., Asgharzdeh, S., Sposto, R., Ji, L., Yanik, G., Mosse, Y.P., Maris, J.M., Park, J.R., London, W., Kreissman, S., Hogarty, M.D. (2010, June 22; Poster). *Is There an Ultra-High-Risk Neuroblastoma group? Report from the Children's Oncology Group (COG) Clinical and Biological Risk Factors (CBRF) Task Force*, Advances in Neuroblastoma Research conference, Stockholm, Sweden.
13. Mestdagh, P., De Preter, K., Vermeulen, J., **Naranjo, A.**, Bray, I., Castel, V., Chen, C., Eggert, A., Hogarty, M.D., London, W.B., Noguera, R., Schramm, A., Schulte, J., Stallings, R., Versteeg, R., Laureys, G., Van Roy, N., Speleman, F., Vandesompele, J. (2010, June 23; Oral). *Improved Outcome Prediction of Children with Neuroblastoma Using a miRNA Signature*, Advances in Neuroblastoma Research conference, Stockholm, Sweden.
14. Yanik, G., Parisi, M., Shulkin, B., **Naranjo, A.**, Kreissman, S., London, W., Villablanca, J., McGrady, P., Matthay, K. (2010, June 24; Oral). *Analyses of MIBG Scoring as a Prognostic Indicator in Patients with Stage 4 Neuroblastoma. A Children's Oncology Group Report (A3973)*, Advances in Neuroblastoma Research conference, Stockholm, Sweden.
15. Granger, M., Grupp, S.A., Kletzel, M., Kretschmar, C., **Naranjo, A.**, London, W.B., and Diller, L. (2010, September 23; Poster). *Feasibility of a Tandem Autologous Peripheral Blood Stem Cell Transplant Regimen for High Risk Neuroblastoma in a Cooperative Group Setting: A Pediatric Oncology Group Study*, Children's Oncology Group Fall 2010 Meeting, Dallas, TX.
16. Irwin, M.S., **Naranjo, A.**, London, W., Seeger, R., Yanik, G., Attiyeh, E.F., Asgharzdeh, S., Mosse, Y.P., Maris, J.M., Park, J., Kreissman, S., and Hogarty, M.D. (2010, September 23; Poster). *Is There an Ultra-High-Risk Neuroblastoma*

Group? : Report from the Children's Oncology Group (COG) Clinical and Biological Risk Factors (CBRF) Task Force, Children's Oncology Group Fall 2010 Meeting, Dallas, TX.

17. Escoto, H., **Naranjo, A.**, London, W.B., McGrady, P., and Kraveka, J.M. (2010, September 23; Poster). *Association of High Ceramide Levels with Unfavorable Neuroblastoma Risk Factors: A Report from the Children's Oncology Group*, Children's Oncology Group Fall 2010 Meeting, Dallas, TX.
18. Wang, L.L., Suganuma, R.^(*), Tovar, J.P., **Naranjo, A.**, London, W.B., Hogarty, M.D., Gastier-Foster, J.M., Look, A.T., Park, J.R., Maris, J.M., Cohn, S.L., and Shimada, H. (2011, February 26; Oral). *Neuroblastoma, Undifferentiated Subtype: A Report from the Children's Oncology Group*, Society for Pediatric Pathology Spring Meeting, San Antonio, TX.
19. Suganuma, R.^(*), Sano, H., Wang, L.L., Tovar, J.P., **Naranjo, A.**, London, W.B., Seeger, R.C., Hogarty, M.D., Gastier-Foster, J.M., Look, T.A., Park, J.R., Maris, J.M., Cohn, S.L., Amann, G., Beiske, K., Cullinane, C.J., d'Amore, E.S.G., Gambini, C., Jarzembowski, J.A., Joshi, V.V., Navarro, S., Peuchmaur, M., and Shimada, H. (2011, September 30; Oral). *Peripheral Neuroblastic Tumors with Genotype-Phenotype Discordance: A Report from Children's Oncology Group and International Neuroblastoma Pathology Committee*, Society for Pediatric Pathology Fall Meeting, Milwaukee, WI.
20. Ostler, K.R., Yang, Q., Vasanthakumar, A., Zhang, L., Looney, T.J., **Naranjo, A.**, Salwen, H., Kocherginsky, M., Lahn, B.T., Cohn, S.L., and Godley, L.A. (2012, April 2; Poster). *A Truncated DNMT3B Protein (DNMT3B7) Drives DNA Methylation and Suppresses Growth in Human Neuroblastoma*, American Association for Cancer Research Annual Meeting, Chicago, IL.
21. Nuchtern, J.G., London, W.B., Barnewolt, C.E., **Naranjo, A.**, Geiger, J.D., Cohn, S.L., and Shamberger, R.C. (2012, April 27; Oral). *A Prospective Study of Expectant Observation as Primary Therapy for Neuroblastoma in Young Infants, a Children's Oncology Group Study*, American Surgical Association Annual Meeting, San Francisco, CA.
22. Ehrlich, P.F., Gow, K., Barnhardt, D., Kandel, J., Hamilton, T., Chen, M., Price, M., **Naranjo, A.**, Perlman, E., Dome, J., and Mullen, E. (2012, May 19; Oral). *Primary Nephrectomy and Intra-Operative Tumor Rupture: Report from the Children's Oncology Group (COG) Renal Tumors Committee*, American Pediatric Surgery Association (APSA) Annual Meeting, San Antonio, TX.
23. Meany, H.J., Attiyeh, E.F., **Naranjo, A.**, Twist, C., London, W.B., Villablanca, J., Schmidt, M.L., Baker, D., Strother, D.R., Shimada, H., Matthay, K.K., Cohn, S.L., Maris, J.M., and Park, J.R. (2012, June 3; Poster). *Outcome Analysis of Non-High-Risk Neuroblastoma Patients Enrolled on Children's Oncology Group Trials P9641 and A3961*, American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL.
24. Wang, L.L., Suganuma, R.^(*), Ikegaki, N., Gastier-Foster, J.M., Hogarty, M.D., Cohn, S.L., Maris, J.M., **Naranjo, A.**, London, W.B., and Shimada, H. (2012, June 19; Oral). *Prominent Nucleolar Formation and N-myc/C-myc Protein Expression in Undifferentiated Neuroblastoma: Immunohistochemical Study Indicates the Worst Prognosis for the Patients with C-myc Positive Tumors – A Report from the Children's Oncology Group*, Advances in Neuroblastoma Research (ANR) Conference, Toronto, ON, Canada.
25. Yanik, G., Shulkin, B., Parisi, M., **Naranjo, A.**, Park, J., Kreissman, S., London, W., Villablanca, J., Cohn, S., and Matthay, K. (2012, June 19; Poster). *Impact of Post-Induction Curie Scores as Prognostic Marker in High Risk Neuroblastoma. A Children's Oncology Group Report*, Advances in Neuroblastoma Research (ANR) Conference, Toronto, ON, Canada.
26. Yanik, G., Shulkin, B., Parisi, M., **Naranjo, A.**, Kreissman, S., London, W., Villablanca, J., Park, J., Cohn, S., and Matthay, K. (2012, June 19; Poster). *MIBG Scoring as a Predictor of Early Relapse or Disease Related Death in High Risk Neuroblastoma. A Children's Oncology Group Report*, Advances in Neuroblastoma Research (ANR) Conference, Toronto, ON, Canada.
27. Schmidt, M.L., Strother, D., Baker, D., **Naranjo, A.**, McGrady, P., London, W., Shimada, H., Cohn, S., Matthay, K., and Maris, J. (2012, June 19; Poster). *Infant Metastatic (4+ 4S) MYCN Non-Amplified Neuroblastoma has a Very High Survival Rate with Moderate Dose Chemotherapy*, Advances in Neuroblastoma Research (ANR) Conference, Toronto, ON, Canada.
28. Attiyeh, E., Meany, H., **Naranjo, A.**, Twist, C., London, W., Villablanca, J., Baker, D., Strother, D.R., Schmidt, M.L., Maris, J., and Park, J. (2012, June 20; Oral). *Outcome Analysis of Non-High-Risk Neuroblastoma Patients Enrolled on Children's Oncology Group Trials P9641 and A3961*, Advances in Neuroblastoma Research (ANR) Conference, Toronto, ON, Canada.

29. Rahamanyian, M., **Naranjo, A.**, Escoto, H., He, Y., London, W.B., Li, L., Clarke, C.J., Wooten-Blanks, L., and Kraveka, J.M. (2012, June 20; Poster). *A Sphingolipidomic Analysis of Neuroblastoma Tumors: Implications for Novel Therapeutic Targets*, Advances in Neuroblastoma Research (ANR) Conference, Toronto, ON, Canada.
30. Nuchtern, J.G., London, W.B., Barnewolt, C.E., **Naranjo, A.**, Geiger, J.D., Cohn, S.L., and Shamberger, R.C. (2012, June 21; Oral). *A Prospective Study of Expectant Observation as Primary Therapy for Neuroblastoma in Young Infants, a Children's Oncology Group Study*, Advances in Neuroblastoma Research (ANR) Conference, Toronto, ON, Canada.
31. Yanik, G., Boubaker, A., Matthay, K., Potschger, U., **Naranjo, A.**, Shulkin, B., Gaze, M., Schmidt, M., and Ladenstein, R. (2012, June 21; Oral). *Curie and SIOOPEN Scoring in Stage 4, High Risk Neuroblastoma. A Report from the Metastatic Imaging Working Group of the International Neuroblastoma Response Criteria (INRC) Committee*, Advances in Neuroblastoma Research (ANR) Conference, Toronto, ON, Canada.
32. Batra, V., Geier, E., Martinez, D., Pawel, B., Yanik, G., **Naranjo, A.**, Giacomini, K., Maris, J.M., Matthay, K.K., and DuBois, S.G. (2012, June 21; Oral). *Norepinephrine Transporter (NET) Protein, but not mRNA, Expression is Correlated with Metaiodobenzylguanidine (MIBG) Avidity in Newly Diagnosed Neuroblastoma (NB) Patients: A Report from the Children's Oncology Group (COG)*, Advances in Neuroblastoma Research (ANR) Conference, Toronto, ON, Canada.
33. Geller, J., Mullen, E., Khanna, G., Ehrlich, P., Cost, N., **Naranjo, A.**, Dome, J., Gratias, E., and Perlman, E. (2012, October 5-6; Poster). *Epidemiology and Characterization of Pediatric and Adolescent Renal Cell Carcinoma: A Report from the Children's Oncology Group Study AREN03B2*, International Kidney Cancer Symposium Meeting, Chicago, IL.
34. Ehrlich, P., Cost, N., Khanna, G., Mullen, E., Gratias, E., **Naranjo, A.**, Dome, J., Perlman, E., and Geller, J. (2012, October 5-6; Poster). *A Description of the Surgical Experience in Children, Adolescents and Young Adults with Renal Cell Carcinoma: A Report from the Children's Oncology Group Study AREN03B2*, International Kidney Cancer Symposium Meeting, Chicago, IL.
35. Kawano, S.^(*), Wang, L., **Naranjo, A.**, London, W., Hogarty, M., Gastier-Foster, J., Look, A., Park, J., Maris, J., Cohn, S., Seeger, R., and Shimada, H. (2013, March 2; Oral). *Mitosis-Karyorrhexis Index (MKI) and MYC Status in Neuroblastoma, with a Special Reference to Intermediate MKI: A Report from the Children's Oncology Group (COG), Society for Pediatric Pathology Spring Meeting*, Baltimore, MD.
36. Hamilton, T.E., Barnhart, D., Gow, K., Ferrer, F., Kandel, J., Glick, R., Dasgupta, R., **Naranjo, A.**, Gratias, E., Geller, J., Mullen, E., and Ehrlich, P. (2013, May 3; Oral). *Quality Assurance of the Real-Time Surgical Reviews of AREN03B2: A COG Renal Tumor Committee Study*, APSA Annual Meeting, Marco Island, FL.
37. Kentsis, A., Burns, M., Eisenberg, A., Ahmed, S., Gaewsky, L., Bradwin, G., He, Y., **Naranjo, A.**, Gadd, S., Warren, P., Rodriguez-Galindo, C., Dome, J., Perlman, E., Steen, H., and Mullen, E. (2013, May 8-10). *Urine Proteomics of Renal Tumors for Discovery of New Prognostic Markers and Therapeutic Targets*, International Conference on Pediatric Renal Tumor Biology, Bethesda, MD.
38. Wang, L.L., Kawano, S., Teshiba, R., He, L., **Naranjo, A.**, London, W.B., Gastier-Foster, J.M., Look, A.T., Hogarty, M.D., Cohn, S.L., Maris, J.M., Park, J.R., and Shimada, H. (2013, September 26-29). *Age-Dependent Prognostic Effect by Mitosis-Karyorrhexis Index (MKI) in Neuroblastoma: A Report from the Children's Oncology Group*, Society for Pediatric Pathology Fall Meeting, Salt Lake City, UT.
39. Wang, L.L., Teshiba, R., He, L., **Naranjo, A.**, London, W.B., Gastier-Foster, J.M., Seeger, R.C., Cohn, S.L., Maris, J.M., Park, J.R., Hogarty, M.D., and Shimada, H. (2013, November 3-6; Poster). *MYCN/MYC Protein Expression in High-MKI (Mitosis-Karyorrhexis Index) Neuroblastomas: A Report from the Children's Oncology Group*, American Association for Cancer Research Special Conference – Pediatric Cancer at the Crossroads: Translating Discovery Into Improved Outcomes, San Diego, CA.
40. Khanna, G., Geller, J., Ehrlich, P., Servaes, S., **Naranjo, A.**, Dome, J., Gratias, E., Perlman, E.J., Cost, N., and Mullen, E. (2014, May 13-17). *Renal Cell Carcinoma in Children and Adolescents: A Summary of Imaging Findings from the Children's Oncology Group*, Society of Pediatric Radiology Annual Meeting, Washington, D.C.
41. de Alarcon, P.A., London, W.B., **Naranjo, A.**, Gorman, M., Panzer, J.A., and Matthay, K.K. (2014, May 15; Oral). *A Randomized Clinical Trial of Cyclophosphamide and Prednisone with or without Intravenous Immunoglobulin (IVIG) for the Treatment of Neuroblastoma Associated Opsoclonus Myoclonus Ataxia Syndrome (OMA): A Children's Oncology Group Trial*, Advances in Neuroblastoma Research (ANR) Conference, Cologne, Germany.
42. **Naranjo, A.**, Shulkin, B., Parisi, M., Park, J., Matthay, K., Glade-Bender, J., Yu, A., and Yanik, G. (2014, May 16; Oral). *Impact of Pre-Immunotherapy Curie Scores on Survival Following Treatment with an Anti-GD2 Antibody (ch14.18)*

and Isotretinoin in High-Risk Neuroblastoma, Advances in Neuroblastoma Research (ANR) Conference, Cologne, Germany.

43. Bagatell, R., McHugh, K., **Naranjo, A.**, Van Ryn, C., Kirby, C., Brock, P., Lyons, K.A., States, L.J., Rojas, Y., Miller, A., Volchenbaum, S., Simon, T., Krug, B., Sarnacki, S., Minard, V., Von Schweinitz, D., Kammer, B., Granata, C., Pio, L., Park, J.R., and Nuchtern, J. (2014, May 16; Oral). *Assessment of Primary Site Response in Children with High Risk Neuroblastoma: An International Multicenter Study*, Advances in Neuroblastoma Research (ANR) Conference, Cologne, Germany.
44. Twist, C.J., London, W.B., **Naranjo, A.**, Schmidt, M.L., Adkins, E.S., Mattei, P., Cohn, S.L., Park, J.R., and Maris, J.M. (2014, May 16; Oral). *Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report from the Children's Oncology Group Study ANBL0531*, Advances in Neuroblastoma Research (ANR) Conference, Cologne, Germany.
45. Wang, L.L., Teshiba, R., **Naranjo, A.**, Ikegaki, N., Tang, X.X., Gastier-Foster, J.M., Asgharzadeh, S., Seeger, R.C., Hogarty, M.D., London, W.B., Cohn, S.L., Park, J.R., Maris, J.M., and Shimada, H. (2014, May 13-16; Poster). *MYCN/MYC Protein Expression in Neuroblastoma, Undifferentiated and Poorly Differentiated Subtype – C-myc Activation is a New Marker for Aggressive Tumor Behavior: A Report from the COG Neuroblastoma Committee*, Advances in Neuroblastoma Research (ANR) Conference, Cologne, Germany.
46. Yanik, G.A., **Naranjo, A.**, Parisi, M.T., Shulkin, B.L., Nadal, H., Gelfand, M., Ladenstein, R., Boubaker, A., Poetschger, U., Valteau-Couanet, D., Kreissman, S.G., Park, J.R., and Matthay, K.K. (2014, May 30-June 3; Poster). *Validation of Post-Induction Curie Scores in High-Risk Neuroblastoma*, American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL.
47. Boubaker, A., Pötschger, U., Lambert, B., Castellani, M., Bar-Sever, Z., Oudoux, A., Kaminska, A., Taborska, K., Biassoni, L., Kreissman, S.G., Yanik, G., Matthay, K.K., **Naranjo, A.**, Park, J., Valteau-Couanet, D., and Ladenstein, R. (2014, May 30-June 3; Poster). *Validation of the MIBG SIOPEX Scoring Method in Two Independent High-Risk Neuroblastoma Trials*, American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL.
48. Twist, C., London, W.B., Naranjo, A., Schmidt, M.L., Adkins, E.S., Mattei, P., Cretella, S., Cohn, S.L., Park, J.R., and Maris, J.M. (2014, May 30-June 3). *Maintaining Outstanding Outcomes using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report from the Children's Oncology Group Study ANBL0531*, American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL.
49. London, W.B., Bagatell, R., Weigel, B., Fox, E., Van Ryn, C., **Naranjo, A.**, Krailo, M.D., Ahern, C.H., and Park, J.R. (2014, May 30-June 3). *Historical Gold Standard for Time-to-Progression (TTP) and Progression-Free Survival (PFS) from Relapsed/Refractory Neuroblastoma Modern Era (2002-14) Patients*, American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL.
50. Mullen, E., Geller, J., Gratias, E., Perlman, E., Ehrlich, P., Khanna, G., **Naranjo, A.**, He, Y., Hamilton, T., Ferrer, F., Glick, R., Gow, K., Barnhardt, D., Kandel, J., Dasgupta, R., Hoffer, F., Serveas, S., Fernandez, C., Grundy, P., and Dome, J. (2014, May 30-June 3; Oral). *Real-Time Central Review: A Report of the First 3,000 Patients Enrolled on the Children's Oncology Group Renal Tumor Biology and Risk Stratification Protocol AREN03B2*, American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL.
51. MacLellan, D., Karakach, T., **Naranjo, A.**, and Fernandez, C.V. (2014, May 30-June 3). *Urinary Metabolite Profiling by Nuclear Magnetic Resonance Spectroscopy Distinguishes Control Patients from Wilms Tumor (WT) and WT Tumor by Stage*, American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL.
52. Paulino, A.C., Gratias, E.J., Fernandez, C.V., Ehrlich, P.F., Gow, K.W., **Naranjo, A.**, Perlman, E.J., Dome, J.S., and Kalapurakal, J.A. (2014, Sept. 14-17; Oral). *Outcomes and Patterns of Failure after Preoperative Chemotherapy for Favorable Histology Wilms Tumor on National Wilms Tumor Study (NWTs)-5*, American Society for Radiation Oncology (ASTRO) Annual Meeting, San Francisco, CA.
53. Boubaker, A., Pötschger, U., Lambert, B., Castellani, M., Bar-Sever, Z., Oudoux, A., Kaminska, A., Taborska, K., Biassoni, L., Kreissman, S.G., Yanik, G., Matthay, K.K., **Naranjo, A.**, Park, J., Valteau-Couanet, D., and Ladenstein, R. (2014, October 20; Oral). *Validation of the MIBG SIOPEX Scoring Method in Two Independent High-Risk Neuroblastoma Trials*, Annual Congress of the European Association of Nuclear Medicine (EANM), Gothenburg, Sweden.
54. Mullen, E., Geller, J., Gratias, E., Perlman, E., Ehrlich, P., Khanna, G., **Naranjo, A.**, Fernandez, C., Grundy, P., and Dome, J. (2014, October 23; Oral). *Comprehensive Update of Pediatric Renal Tumor Epidemiology: Analysis of the First*

- 4000 Patients on Children's Oncology Group (COG) Renal Tumor Classification and Biology Protocol AREN03B2, Congress of the International Society of Paediatric Oncology (SIOP), Toronto, Canada.
55. Ehrlich, P.F., Mullen, E., Geller, J., **Naranjo, A.**, Gratiyas, E., Barnhart, D., Dasgupta, R., Ferrar, F., Gow, K., Hamilton, T., Kandel, J., He, Y., Perlman, E., Khanna, G., Hoffer, F., Servaes, S., Kalapurakal, J., and Dome, J.S. (2014, October 23; Oral). *Unilateral Wilms Tumor Treated by Partial Nephrectomy Enrolled on the Children's Oncology Group (COG) Renal Tumor Biology and Classification Study AREN03B2*, Congress of the International Society of Paediatric Oncology (SIOP), Toronto, Canada.
56. Galli, S., Tilan, J., **Naranjo, A.**, Van Ryn, C., Yang, C., Tsuei, J., Trinh, E., and Kitlinska, J. (2015, March). *Association of Neuropeptide Y (NPY) and its Receptors with Prognostic Factors and Survival in Neuroblastoma Patients*, United States and Canadian Academy of Pathology (USCAP), Boston, MA.
57. Wang, L.L., Teshiba, R., Ikegaki, N., Tang, X.X., **Naranjo, A.**, London, W.B., Hogarty, M.D., Gastier-Foster, J.M., Look, A.T., Park, J.R., Maris, J.M., Cohn, S.L., Seeger, R.C., Asgharzadeh, S., and Shimada, H. (2015, January 7-10; Poster). *Immunohistochemical Detection of MYCN Protein and MYC Protein Identifies Highly Aggressive Neuroblastomas*, AACR Special Conference on MYC: From Biology to Therapy, La Jolla, CA.
58. Yanik, G.A., **Naranjo, A.**, Parisi, M.T., Shulkin, B.L., Nadel, H., Gelfand, M.J., Ladenstein, R., Boubaker, A., Poetschger, U., Valteau-Couanet, D., Kreissman, S.G., Park, J.R., and Matthay, K.K. (2015, February). *Impact of Post-Induction Curie Scores in High-Risk Neuroblastoma*, American Society for Blood and Marrow Transplantation (ASBMT) Tandem Meetings, San Diego, CA.
59. Teshiba, R., Wang, L.L., Ikegaki, N., Tang, X.X., **Naranjo, A.**, London, W.B., Hogarty, M.D., Gastier-Foster, J.M., Look, A.T., Park, J.R., Maris, J.M., Cohn, S.L., Seeger, R.C., Asgharzadeh, S., and Shimada, H. (2015, March 21-22; Oral). *Immunohistochemical Profile of MYCN/MYC Protein Expression in Neuroblastoma with High Mitosis-Karyorrhexis Index: A Report from the Children's Oncology Group Neuroblastoma Study*, Society for Pediatric Pathology Spring Meeting, Boston, MA.
60. Galli, S., Tilan, J., **Naranjo, A.**, Van Ryn, C., Yang, C., Tsuei, J., Trinh, E., and Kitlinska, J.B. (2015, April 18-22). *Neuropeptide Y (NPY) and its Receptor Expression in Neuroblastoma Patients – Associations with Disease Prognosis and Patients' Survival*, Annual Meeting of the American Association for Cancer Research (AACR), Philadelphia, PA.
61. Oldridge, D.A., Eleveld, T.F., Bernard, V., Koster, J., Daage, L.C., Diskin, S.J., Schild, L., Bentahar, N.B., Bellini, A., Chicard, M., Lapouble, E., Combaret, V., Legoix-Né, P., Michon, J., Pugh, T.J., Hart, L.S., Rader, J., Attiyeh, E.F., Wei, J.S., Zhang, S., **Naranjo, A.**, Gastier-Foster, J.M., Hogarty, M.D., Smith, M.A., Auvil, J.M.G., Watkins, T.B.K., Zwijnenburg, D.A., Ebus, M.E., van Sluis, P., Hakkert, A., van Wezel, E., van der Schoot, C.E., Westerhout, E.M., Schulte, J.H., Tytgat, G.A., Dolman, M.E.M., Janoueix-Lerosey, I., Gerhard, D.S., Caron, H.N., Delattre, O., Khan, J., Versteeg, R., Schleiermacher, G., Maris, J.M., and Molenaar, J.J. (2015, April 18-22). *Relapsed Neuroblastomas Show Frequent RAS-MAPK Pathway Mutations*, Annual Meeting of the American Association for Cancer Research (AACR), Philadelphia, PA.
62. Shusterman, S., London, W.B., Hank, J.A., Parisi, M.T., Shulkin, B.L., Servaes, S., **Naranjo, A.**, Shimada, H., Gan, J., Gillies, S.D., Maris, J.M., Park, J.R., and Sondel, P.M. (2015, June 1; Oral). *A Feasibility and Phase II Study of the hu14.18-IL2 Immunocytokine in Combination with GM-CSF and Isotretinoin in Patients with Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Study*, American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL.
63. Nuchtern, J., Bagatelle, R., McHugh, K., **Naranjo, A.**, Van Ryn, C., Rojas, Y., Lyons, K., Guillerman, P., Kirby, C., and Brock, P. (2015, October 9; Oral). *A Subset of Image Defined Risk Factors Predicts Completeness of Resection in Children with High-Risk Neuroblastoma: An International Multicenter Study*, Congress of the International Society of Paediatric Oncology (SIOP), Cape Town, South Africa.
64. Applebaum, M.A., Vaksman, Z., Hungate, E., Henderson, T.O., London, W.B., Pinto, N.R., Volchenboum, S.L., Park, J.R., **Naranjo, A.**, Pearson, A.D.J., Hero, B., Cohn, S.L., and Diskin, S. (2016, June 6; Poster). *Second Malignancies in Patients with Neuroblastoma: A Report from the International Neuroblastoma Risk Group Project*, American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL.
65. Park, J.R., Kreissman, S.G., London, W.B., **Naranjo, A.**, Cohn, S.L., Hogarty, M.D., Teeney, S.C., Haas-Kogan, D., Shaw, P.J., Geiger, J.D., Doski, J.J., Gorges, S.W., Khanna, G., Voss, S.D., Maris, J.M., Grupp, S.A., and Diller, L. (2016, June 5; Oral). *A Phase III Randomized Clinical Trial (RCT) of Tandem Myeloablative Autologous Stem Cell Transplant (ASCT) Using Peripheral Blood Stem Cell (PBSC) as Consolidation Therapy for High-Risk Neuroblastoma (HR-*

NB): A Children's Oncology Group (COG) Study, American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL.

66. Mody, R., **Naranjo, A.**, Van Ryn, C., Yu, A., London, W.B., Shulkin, B.L., Parisi, M.T., Serves, S., Diccianni, M.B., Sondel, P.M., Maris, J.M., Park, J.R., and Bagatell, R. (2016, June 3; Oral). *Phase II Randomized Trial of Irinotecan/Temozolomide (I/T) with Temsirolimus (TEM) or Dinutuximab Plus Granulocyte Colony Stimulating Factor (DIN/GMCSF) in Children with Refractory or Relapsed Neuroblastoma: A Report from the Children's Oncology Group (COG)*, American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL.
67. DuBois, S.G., Mody, R., Van Ryn, C., **Naranjo, A.**, Kreissman, S.G., Baker, D., Parisi, M.T., Shulkin, B.L., Maris, J.M., Batra, V., Park, J.R., Matthay, K.K., and Yanik, G.A. (2016, June 6; Poster). *Clinical, Biologic, and Outcome Differences According to MIBG Avidity in Children with Neuroblastoma: A Report from the Children's Oncology Group (COG)*, American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL.
68. Pinto, N.R., Emond, M.J., Spiekerman, C., **Naranjo, A.**, Makar, K.W., Park, J., and McCune, J.S. (2016, June 6; Poster). *Pharmacogenetics of Treatment Response in Patients with High-Risk Neuroblastoma, A Children's Oncology Group Study*, American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL.
69. Federico, S.M., Chen, X., Easton, J., Wu, J., Mao, S., Liu, Y., **Naranjo, A.**, Pappo, A.S., Hogarty, M.D., and Dyer, M.A. (2016, June 6; Poster). *Association of Age at Diagnosis and Stage of Disease with ATRX Mutations in Neuroblastoma*, American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL.
70. Granger, M., Yanik, G.A., **Naranjo, A.**, McCune, J.S., Dubois, S.G., Bagatell, R., Weiss, B.D., Grupp, S.A., Tenney, S.C., Asgharzadeh, S., Hogarty, M.D., Panoff, J.E., Chang, J.H., Gastier-Foster, J.M., Mills, D., and Park, J.R. (2016, June 6; Poster). *Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients with High-Risk Neuroblastoma: A Children's Oncology Group (COG) Study*, American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL.
71. DuBois, S.G., Mody, R., Van Ryn, C., **Naranjo, A.**, Kreissman, S., Baker, D.L., Parisi, M., Shulkin, B., Maris, J.M., Batra, V., Park, J.R., Matthay, K.K., and Yanik, G. (2016, June 21; Oral). *Clinical, Biologic, and Outcome Differences According to MIBG Avidity in Children with Neuroblastoma: A Report from the Children's Oncology Group (COG)*, Advances in Neuroblastoma Research (ANR) Congress, Cairns, Australia.
72. Cho, H., Yang, S., Sonawane, P., Yu, A.L., Park, J.R., Kreissman, S., **Naranjo, A.**, Van Ryn, C., Villablanca, J.G., Reynolds, P., and Kang, M.H. (2016, June 21; Poster). *Pharmacokinetics (PK) of 13-cis Retinoic Acid in COG Phase III Neuroblastoma Studies*, Advances in Neuroblastoma Research (ANR) Congress, Cairns, Australia.
73. Wang, L.L., Teshiba, R., Matsuno, R., Ikegaki, N., Van Ryn, C., **Naranjo, A.**, London, W.B., Hogarty, M.D., Gastier-Foster, J.M., Look, A.T., Park, J.R., Maris, J.M., Cohn, S.L., Seeger, R.C., Asgharzadeh, S., and Shimada, H. (2016, June 21; Poster). *High-MKI Neuroblastomas - MYC-Family-Driven Tumors with Augmented Expression of MYCN/MYC Protein Behaves More Aggressively than Non-MYC-Family-Driven Tumors: A Report from the Children's Oncology Group*, Advances in Neuroblastoma Research (ANR) Congress, Cairns, Australia.
74. Twist, C.J., Adkins, E.S., Mattei, P., Wootton-Gorges, S.L., Hoffer, F.A., **Naranjo, A.**, Schmidt, M.L., Hogarty, M.D., Irwin, M.S., Cohn, S.L., Park, J.R., Maris, J.M. (2016, June 21; Poster). *Validation of Image-Defined Risk Factor (IDRF) Assignment in Patients with Intermediate-Risk Neuroblastoma: A Report from the Children's Oncology Group Study ANBL0531*, Advances in Neuroblastoma Research (ANR) Congress, Cairns, Australia.
75. Granger, M., **Naranjo, A.**, McCune, J.S., Dubois, S.G., Bagatell, R., Weiss, B.D., Grupp, S.A., Cretella, S., Mosse, Y.P., Asgharzadeh, S., Hogarty, M., Panoff, J., Chang, J.H., London, W., Gastier-Foster, J.M., Mills, D., Park, J.R., and Yanik, G. (2016, June 22; Oral). *Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients with High-Risk Neuroblastoma. A Children's Oncology Group (COG) Study*, Advances in Neuroblastoma Research (ANR) Congress, Cairns, Australia.
76. Pötschger, U., **Naranjo, A.**, Yanik, G., Castellani, M., Boubaker, A., Lambert, B., Lewington, V., Bar-Sever, Z., Oudoux, A., Kaminska, A., Taborska, K., Biassoni, L., Parisi, M.T., Shulkin, B.L., Nadel, H.R., Gelfand, M.J., Park, J.R., Kreissman, S.G., Valteau-Couanet, D., Matthay, K.K., and Ladenstein, R. (2016, June 23; Oral). *The Way Towards an International mIBG Skeletal Score for High Risk Neuroblastoma: The Statistical Perspective*, Advances in Neuroblastoma Research (ANR) Congress, Cairns, Australia.
77. Park, J.R., Kreissman, S.G., London, W.B., **Naranjo, A.**, Cohn, S.L., Hogarty, M.D., Tenney, S.C., Haas-Kogan, D., Shaw, P.J., Doski, J., Geiger, J., Gorges, S.W., Khanna, G., Voss, S., Maris, J.M., Diller, L., and Grupp, S. (2016, June 23; Oral). *A Phase 3 Randomized Clinical Trial (RCT) of Tandem Myeloablative Autologous Stem Cell Transplant (ASCT)*

- Using Peripheral Blood Stem Cell (PBSC) as Consolidation Therapy for High-Risk Neuroblastoma (HR-NB): A Children's Oncology Group (COG) Study*, Advances in Neuroblastoma Research (ANR) Congress, Cairns, Australia.
78. Mody, R., **Naranjo, A.**, Van Ryn, C., London, W.B., Yu, A., Shulkin, B.L., Parisi, M.T., Serves, S., Diccianni, M., Sondel, P.M., Maris, J.M., Park, J.R., and Bagatell, R. (2016, June 23; Oral). *Phase II Randomized Trial of Irinotecan/Temozolomide (I/T) with Temsirolimus (TEM) or Dinutuximab Plus Granulocyte Colony Stimulating Factor (DIN/GMCSF) in Children with Refractory or Relapsed Neuroblastoma: A Report from the Children's Oncology Group (COG)*, Advances in Neuroblastoma Research (ANR) Congress, Cairns, Australia.
79. Applebaum, M.A., Vaksman, Z., Hungate, E., Henderson, T.O., London, W.B., Pinto, N.R., Volchenbom, S.L., Park, J.R., **Naranjo, A.**, Pearson, A.D.J., Hero, B., Cohn, S.L., and Diskin, S. (2016, June 23; Oral). *Second Malignancies in Patients with Neuroblastoma: A Report from the International Neuroblastoma Risk Group Project*, Advances in Neuroblastoma Research (ANR) Congress, Cairns, Australia.
80. Pinto, N., Emond, M.J., Spiekerman, C., **Naranjo, A.**, Makar, K., Park, J., and McCune, J.S. (2016, June 23; Oral). *Pharmacogenetics of Treatment Response in Patients with High-Risk Neuroblastoma, A Children's Oncology Group Study*, Advances in Neuroblastoma Research (ANR) Congress, Cairns, Australia.
81. Irwin, M.S., **Naranjo, A.**, Van Ryn, C., Cohn, S.L., London, W.B., Gastier-Foster, J., Matthay, K.K., Attiyeh, E.F., Maris, J.M., Bagatell, R., Park, J.R., and Hogarty, M.D. (2016, June 23; Oral). *Revised Children's Oncology Group (COG) Risk Stratification Incorporating the International Neuroblastoma Risk Group Staging System*, Advances in Neuroblastoma Research (ANR) Congress, Cairns, Australia.
82. Pötschger, U., **Naranjo, A.**, Yanik, G., Castellani, M., Boubaker, A., Lambert, B., Lewington, V., Kaminska, A., Taborska, K., Parisi, M., Shulkin, B., Park, J., Kreissman, S., Matthay, K., and Ladenstein, R. (2016, October 16; Oral). *Towards an International mIBG Skeletal Score for High Risk Neuroblastoma: A SIOPEN-COG Cooperation*, European Association of Nuclear Medicine Annual Congress, Barcelona, Spain.
83. Irwin, M.S., **Naranjo, A.**, Van Ryn, C., Cohn, S.L., London, W.B., Gastier-Foster, J., Matthay, K.K., Attiyeh, E.F., Maris, J.M., Bagatell, R., Park, J.R., and Hogarty, M.D. (2016, October 21; Oral). *Revised Children's Oncology Group (COG) Risk Stratification Incorporating the International Neuroblastoma Risk Group Staging System*, Congress of the International Society of Paediatric Oncology, Dublin, Ireland.
84. Granger, M., **Naranjo, A.**, McCune, J.S., Dubois, S.G., Bagatell, R., Weiss, B.D., Grupp, S.A., Cretella, S., Mosse, Y.P., Asgharzadeh, S., Hogarty, M., Panoff, J., Chang, J.H., London, W., Gastier-Foster, J.M., Mills, D., Park, J.R., and Yanik, G. (2016, October 22; Oral). *Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients with High-Risk Neuroblastoma. A Children's Oncology Group (COG) Study*, Congress of the International Society of Paediatric Oncology, Dublin, Ireland.
85. Pötschger, U., **Naranjo, A.**, Yanik, G., Castellani, M., Boubaker, A., Lambert, B., Lewington, V., Kaminska, A., Taborska, K., Parisi, M., Shulkin, B., Park, J., Kreissman, S., Matthay, K., and Ladenstein, R. (2016, October 22; Oral). *The Way Towards an International mIBG Skeletal Score for High Risk Neuroblastoma: The Statistical Perspective*, Congress of the International Society of Paediatric Oncology, Dublin, Ireland.
86. Reville, P.K., Erbe, A.K., Wang, W., Carmichael, L., Kim, K., London, W.B., **Naranjo, A.**, Hank, J.A., DiCianni, M., Hogarty, M.D., Park, J.R., Yu, A.L., and Sondel, P.M. (2017, February 27-28; Poster). *KIR/KIR-Ligand Genotypes Influence Clinical Response to Dinutuximab-Based Immunotherapy in High-Risk Neuroblastoma Patients*, Frontiers in Cancer Immunotherapy Meeting, New York, NY.
87. Erbe, A.K., Wang, W., Carmichael, L., Kim, K., Reville, P.K., London, W.B., Hank, J.A., Diccianni, M.B., **Naranjo, A.**, Hogarty, M.D., Park, J.R., Yu, A.L., and Sondel, P.M. (2017, April 1-5; Poster). *Impact of KIR/KIR Ligand Genotype for Neuroblastoma Patients in a Phase 3 COG Immunotherapy Trial*, American Association for Cancer Research (AACR) Annual Meeting, Washington, D.C.
88. Ortiz, M.V., Burns, M., Eisenberg, A., Ahmed, S., Gaewsky, L., Bradwin, G., Cifani, P., Henssen, A., Macarthur, I., LaQuaglia, M., Letai, A., **Naranjo, A.**, Gadd, A., Chi, Y., Dome, J., Perlman, E., Mullen, E., Steen, H., and Kentsis, A. (2017, April 1-5; Poster). *Prohibitin is a Prognostic Marker of Treatment Failure and Therapeutic Target to Block Chemotherapy Resistance in Wilms Tumor*, American Association for Cancer Research (AACR) Annual Meeting, Washington, D.C.
89. Cho, H., **Naranjo, A.**, Van Ryn, C., Yang, S., Sonawane, P., Villablanca, J.G., Yu, A.L., Park, J.R., Kreissman, S., Reynolds, C.P., and Kang, M.H. (2017, April 1-5; Oral/Poster). *Low Plasma Levels of 13-Cis-Retinoic Acid (Isotretinoin) and its Active Metabolite 4-Oxo-13-Cis-Retinoic Acid Are Associated with Lower Overall Survival of High-*

Risk Neuroblastoma Patients, American Association for Cancer Research (AACR) Annual Meeting, Washington, D.C.

Funding History

Ongoing

"Children's Oncology Group Statistics and Data Center", National Institutes of Health (NIH)/National Cancer Institute (NCI) U10 CA180899

PI: Devidas, M. 3/1/2014 – 2/28/2019

Role: Principal Investigator on the University of Florida subaccount

The major goals of this project are to collaborate in the design, data monitoring, and publication of childhood cancer clinical trials and biological studies.

"Isotretinoin Pharmacokinetics and Pharmacogenomics in High-Risk Neuroblastoma", NIH/NCI R01 CA168699

PI: Kang, M. 8/1/2013 – 7/31/2017

Role: Principal Investigator on the subcontract from Texas Tech University to the University of Florida

The goal of this project is to determine whether the plasma levels of 13-cis-RA and its metabolites achieved in high-risk neuroblastoma patients is associated with outcome, patient demographics and biologic characteristics, generic formulation, and opening of the capsules for drug administration.

"Late Effects After High Risk Neuroblastoma – The LEAHRN Study", St. Baldrick's Foundation

PI: Henderson, T. 07/01/2015–06/30/2017

Role: Principal Investigator on the subcontract from the University of Chicago to the University of Florida

The goal of this study is to identify a large cohort of patients with high-risk neuroblastoma who have survived relapse-free long-term following treatment in order to evaluate the late effects of therapies.

Submitted

"Tumor and Host Markers of Clinical Outcomes After MIBG Therapy in Neuroblastoma", NIH/NCI R01 CA214912

PI: Dubois, S. 9/1/2017 – 8/31/2022

Role: Principal Investigator on the subcontract from Harvard Medical School to the University of Florida

The goal of this project is to determine whether biologic and genomic features of neuroblastoma patients can predict response and toxicity from MIBG therapy in patients with high-risk newly diagnosed neuroblastoma.

"Characterization of a Panel of Neuroblastoma Xenograft Models for Preclinical Therapeutic Studies", NIH/NCI R01 PAR-14-241

PI: Kang, M. 4/1/2016–3/31/2019

Role: Principal Investigator on the subcontract from Texas Tech University to the University of Florida

The goal of this project is to characterize the genomics on a panel of COG cell lines and patient-derived xenografts and link with response to therapy.

"Computerized Microscopic Image Analysis as a Tool for Refined Risk Stratification in Neuroblastoma", NIH/NCI R21 PAR-12-145

PI: Weiser, D. 4/1/2016–3/31/2018

Role: Principal Investigator on the subcontract from Yeshiva University to the University of Florida

The goal of this project is to apply digital image analysis software to identify distinct biological features present at diagnosis in primary refractory neuroblastoma to define highly aggressive disease.

"Developmental Patterns of Hookah Use and Implications for Policy", Department of Health and Human Services

PI: Barnett, T.

Role: Biostatistician

The goal of this project is to study young adults' tobacco use patterns, focusing particularly on those who initiate with an emerging product, including hookah, e-cigarettes, or cigars/cigarillos.

Completed

“The Genetic Basis of Neuroblastoma Tumorigenesis (GWAS)”, NIH/NCI R01 CA124709

PI: Maris, J. 4/1/2015–3/31/2017

Role: Principal Investigator on the subcontract from Children’s Hospital of Philadelphia to University of Florida

The goal of this project is to determine the genetic basis of neuroblastoma to improve outcomes by understanding the essential mechanisms of cancer formation and progression and to use this knowledge to develop novel therapies.

“Molecular Diagnostics for Risk Stratification and Monitoring of Neuroblastoma”, NIH/NCI

PI: Asgharzadeh, S. 3/4/2015–2/28/2017

Role: Principal Investigator on the subcontract from Children’s Hospital of Los Angeles to University of Florida

The goal of this project is to validate the clinical utility of two new molecular diagnostic gene detection signatures developed for determining prognosis and monitoring response to therapy for patients with stage 4 tumors.

“The Interactive International Neuroblastoma Risk Group [INRG] Database”, St. Baldrick’s Foundation

PI: Cohn, S. 7/1/2013 – 6/30/2016

Role: Principal Investigator on the subcontract from the University of Chicago to the University of Florida

The major goal is to support the data de-identification, clean-up, and exports for the INRG database. This includes data management, programming, and analytic support for other neuroblastoma biological, genomic, surgical, and imaging projects of the COG.

“Children’s Oncology Group Statistics and Data Center”, National Institutes of Health (NIH)/National Cancer Institute (NCI) U10 CA98413

PI: Anderson, J.R. 3/1/2008 – 2/28/2014

Role: Co-Investigator on the subcontract to the University of Florida

The major goals of this project are to collaborate in the design, data monitoring, and publication of childhood cancer clinical trials and biological studies.

“Children’s Oncology Group Statistics and Data Center – Neuroblastoma Virtual Tumor Bank”, CureSearch for Children’s Cancer

PI: **Naranjo, A.** 3/1/2013 – 2/28/2014

Role: Principal Investigator

The goals of this project are to perform novel correlative studies on recently closed neuroblastoma trials anticipated to impact the approach to therapy of high risk disease. Collaboration on an international effort across clinical trials worldwide to analyze the impact of these novel markers of response in predicting outcome will also be undertaken.

“Faculty Enhancement Opportunity (FEO) award”, University of Florida

PI: **Naranjo, A.** 12/3/2012 – 12/7/2012

This award was given to attend Deming Conference on Applied Statistics in Atlantic City, NJ. I attended sessions on biomarker development, validation, and analysis; group sequential design; sensitivity analysis for missing data; adaptive clinical trial design; and a short course on missing data in clinical trials.

“Statistics and Data Center Grant Research Supplement to Promote Diversity”, NIH/NCI U10 CA98413-08S2

PI: **Naranjo, A.** 9/1/2010 – 2/28/2011

Role: Principal Investigator on the subcontract to the University of Florida

The goal of this project is to improve the diversity of the research workforce in scientific fields by supporting underrepresented racial and ethnic groups. Specifically, funding from this project was used to develop an individual research program focusing on statistical methodologies applicable to clinical trials.

“Neuroblastoma Virtual Tumor Bank”, University of Chicago

PI: **Naranjo, A.** 7/1/2008 – 1/20/2011

Role: Principal Investigator on the subcontract to the University of Florida

The major goal is to provide statistical support for the creation and maintenance of the COG Neuroblastoma Virtual Tumor Bank (VTB). This includes specimen selection and linkage of clinical and outcome data to the specimen data.

“Universal Cognitive-Behavioral Intervention for Elementary Students to Reduce Disruptive/Aggressive Behavior”, National Center for Special Education Research, Institute for Education Sciences, U.S. Department of Education R324B060029

PI: Smith, S. 08/01/2006 – 07/31/2010

Role: Statistical Analyst

The major goal is to determine whether a universally applied classroom-based curriculum can reduce disruptive/aggressive behavior among 4th and 5th grade students, particularly those with high behavioral risk profiles.

“Neuroblastomas TARGET Initiative”, NIH/NCI U10 CA98543

PI: Reaman, G.H. 2/21/2008 – 2/20/2010

Role: Co-Investigator on the subcontract to the University of Florida

The major goals were to collaborate in the microarray analysis of gene expression data to identify new molecular targets for development of novel therapies for neuroblastoma. We selected specimens from the COG Neuroblastoma VTB database and collaborated on manuscripts and development of novel clinical trials.

“Statistical Support for COG Acute Lymphoblastic Leukemia and Neuroblastoma Clinical Trials”, Department of Energy/National Childhood Cancer Foundation DE-FG02-08ER64718

PI: Reaman, G.H. 9/30/2008 – 9/29/2009

Role: Co-Investigator on the subcontract to the University of Florida

The major goals were to conduct statistical analysis and develop new methodologies in childhood cancer clinical trials in the areas of acute lymphoblastic leukemia and neuroblastoma.

“Prognostic Indicators in Lupus Nephritis”, Lupus Research Institute 00018998

PI: Richards, H. 09/01/2002 – 07/31/2006

Role: Statistical Analyst

The major goals of this study are to learn if any immune system markers predict the development of kidney disease in lupus patients, as well as determine if the selected markers tested over time predict whether standard treatments are effective in treating lupus kidney disease.

COG Protocols

Lead Statistician for neuroblastoma and study statistician on the following COG protocols:

- ANBL00B1, ANBL00P3, ANBL0032, ANBL0531, ANBL0532, ANBL09P1, ANBL0931, ANBL1021, ANBL12P1, ANBL1221, ANBL1232, ANBL1531, ABTR01B1, ABTR04B1, and ALTE15N2

Teaching

| <u>Course</u> | <u>Title</u> | <u>Credits</u> | <u>Semester</u> | <u>Students</u> |
|-----------------------------|--|----------------|-----------------|-----------------|
| GMS 6818 (co-instructor) | Design and Conduct of Clinical Trials I | 2 | Spring 2010 | 8 |
| | | | Spring 2011 | 6 |
| | | | Spring 2012 | 12 |
| | | | Spring 2013 | 3 |
| | | | Fall 2013 | 10 |
| | | | Fall 2014 | 13 |
| | | | Fall 2015 | 13 |
| GMS 6819 (co-instructor) | Design and Conduct of Clinical Trials II | 2 | Fall 2010 | 10 |
| | | | Fall 2011 | 13 |
| | | | Fall 2012 | 13 |
| | | | Spring 2014 | 6 |
| | | | Spring 2015 | 4 |
| | | | Spring 2016 | 6 |
| PHC 6937 (co-instructor) | Design and Conduct of Clinical Trials | 3 | Fall 2016 | 16 |

Guest Lectures

- “Power and Sample Size Analysis: A General Overview with Introduction to Case-Control Studies and Epi-Info”, Feb. 19, 2009. Guest lecture in GMS 6826: Advanced Design and Methodology for Case-Control Studies (Instructor: Stephanie Staras).
- “Power and Sample Size Analysis: A General Overview with Introduction to Case-Control Studies and SAS Power & Sample Size”, Feb. 11, 2010. Guest lecture in GMS 6826: Advanced Design and Methodology for Case-Control Studies (Instructor: Stephanie Staras).
- “Clinical Trials: Phase I through IV”, July 15, 2011. Invited lecture in GMS 7093: Introduction to Clinical and Translational Research (Moderator: Ronald Shorr).

Master’s Thesis Committees and Graduate Students

M.S. Committee Chair

- Hui Yan (Biostatistics, University of Florida), M.S. earned May 2013
- Shuo Zhang (Biostatistics, University of Florida), M.S. earned May 2014
- Anjali Thakur (M.P.H., Biostatistics Concentration, University of Florida), degree earned May 2016
- Zhennan Zhu (Biostatistics, University of Florida), M.S. earned May 2017
- Mingjin Liu (Biostatistics, University of Florida), M.S. expected May 2018

Graduate Students

- Ying He (Biostatistics, University of Florida), Ph.D. earned Dec. 2014. COG graduate assistant from June 2011–December 2014. Taught how to write technical and study progress reports, SAS programming, and statistical methodology in the areas of neuroblastoma and renal tumors for COG.
- Qian Sun (Biostatistics, University of Florida), M.S. committee member, degree earned May 2016

Educational Development

- “Rare Paediatric Tumour Clinical Trial Design Workshop”, May 12–13, 2010, University of Birmingham, England. The workshop brought together statisticians from COG and other international cooperative groups actively involved in clinical trials for children with cancer to consider how to apply innovative trial methodology in the small patient populations and relatively high survival rates encountered in pediatric oncology.
- “Faculty as Teachers”, Sept. 21, 2011 – 3 hour workshop providing the essentials of teaching and learning: setting expectations for learners, teaching skills for active learning, giving effective feedback to learners and assessing learning. Part of the UF Health Science Center Faculty Educational Development certificate series.
- “Enhancing the Lecture Format”, Oct. 19, 2011 – 1.5 hour workshop. Part of the UF Health Science Center Faculty Educational Development certificate series.
- “Teaching and Learning through Classroom Discussions”, Oct. 17, 2012 – 1.5 hour workshop exploring best practices for facilitating discussion and how to use discussions as assessment. Part of the UF Information Technology Teaching Excellence Workshop series.
- Won the Fall 2012 University of Florida Faculty Enhancement Opportunity (FEO) award to attend the Deming Conference on Applied Statistics in Atlantic City, NJ (Dec. 3–7, 2012). Attended sessions on biomarker development, validation, and analysis; group sequential design; sensitivity analysis for missing data; adaptive clinical trial design; and a short course on missing data in clinical trials.
- “Communication for Managers,” Feb. 12, 2015 – 3 hour workshop identifying key issues, challenges, and strategies to help managers communicate effectively with team members. Part of the UF Leadership Development program.

Service

COG Committees

- Neuroblastoma Disease, 2008–present
- Neuroblastoma Steering, 2008–present
- Neuroblastoma Biology, 2008–present
- Renal Tumors Disease, 2010–2014
- Renal Tumors Biology, 2010–2014
- Young Investigators, 2009–2012
- ad hoc Scientific Council concept reviewer, 2009–present
- International Neuroblastoma Clinical Trials Planning Meeting (CTPM) Metastatic Imaging Working Group, 2012–present
- International Neuroblastoma CTPM Primary Tumor/Soft Tissue Working Group, 2012–2016

University of Florida Committees

- College of Medicine Faculty Council, 2014–present
- College of Public Health & Health Professions Faculty Council, 2011–2014
- Presidential Committee, Lesbian, Gay, Bisexual, Transgender Concerns, 2010–2013
- ad hoc abstract judge for College of Public Health & Health Professions Research Day, 2012–2013
- College of Public Health & Health Professions Diversity ad hoc Committee, 2012–2014

Departmental Committees

- Public Relations Committee, Chair, 2013–present
- Student Recruitment Committee, 2013–present
- Committee to foster Biostatistics faculty mentoring opportunities in the Interdisciplinary Degree Program (IDP), Advanced Postgraduate Program in Clinical Investigation (APPCI), and other College of Medicine student Ph.D. and Master's committees, 2010
- Search committees to hire Statistical Research Coordinators, 2009–2010, 2012, 2013
- Search committee to hire Program Assistant, 2011
- Search committees to hire statistical Research Assistants, 2011–2017

Community Service

- Alachua County Public Schools science fair judge, 2009–2010, 2012